Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.
Sponsor: Biogen
Terminated
Low recruitment
This PHASE1 trial investigates Pulmonary; Hypertension and Systemic Sclerosis and is currently terminated or withdrawn. Biogen leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE1
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
▶ Show 4 earlier versions
-
Mar 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- Robert Lafyatis
For direct contact, visit the study record on ClinicalTrials.gov .